NGN282 phase-2 data in NASH: https://www.prnewswire.com/news-releases/ngm-bio-announces-results-from-phase-2-study-of-ngm282-in-nash-patients-demonstrating-clinically-significant-improvements-in-liver-histology-after-12-weeks-300629544.html